Drugs / SOR-C13
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03784677 | Jul 2019 → Jun 2023 | digestive system carcinoma, ovarian carcinoma, prostate cancer, refractory malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01578564 | Jul 2012 → Jul 2015 | cancer | Soricimed Biopharma Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-12-17 | Soricimed Biopharma Inc | Soricimed to Investigate the Potential Benefit of SOR-C13 in the Treatment of COVID-19 soricimed.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOR-C13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01578564 ↗ |
| Action | Inhibit | “TRPV6 calcium channel inhibitor SOR-C13” NCT03784677 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4228250 ↗ |
| Route | Intravenous | “when given as an intravenous infusion” NCT01578564 ↗ |